Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
12:48pm, Friday, 29'th Apr 2022
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
Gilead Sciences (GILD) Q1 2022 Earnings Call Transcript
06:00am, Friday, 29'th Apr 2022 The Motley Fool
GILD earnings call for the period ending March 31, 2022.
Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates
09:25pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2022 Results - Earnings Call Transcript
09:15pm, Thursday, 28'th Apr 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commerc
Gilead Sciences (GILD) Beats Q1 Earnings and Revenue Estimates
06:48pm, Thursday, 28'th Apr 2022
Gilead (GILD) delivered earnings and revenue surprises of 19.77% and 6.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Boomers are leaving the stock market. Here's what comes next, says this strategist.
02:11pm, Thursday, 28'th Apr 2022 MarketWatch
Our call of the day from TS Lombard chief economist Steven Blitz warns that the "golden era of Fed-controlled equity markets" is nearing an end.
How Gilead is positioning Veklury against COVID-19 antivirals like Paxlovid
01:02pm, Thursday, 28'th Apr 2022 MarketWatch
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Is the S&P 500 All You Need to Retire a Millionaire?
12:10pm, Thursday, 28'th Apr 2022 The Motley Fool
Spoiler: Yup! No fancy degrees or risky investments are needed to build wealth and financial security.
CDC study highlights speed with which omicron variant infected Americans, and WHO warns testing is still crucial
10:27am, Thursday, 28'th Apr 2022 MarketWatch
A report from the Centers for Disease Control and Prevention is highlighting just how many Americans have been infected with COVID-19, and how much the number increased since the arrival of the highly
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
06:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News
04:44pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
03:18pm, Wednesday, 27'th Apr 2022
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Should You Buy Gilead (GILD) Ahead of Earnings?
12:38pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
